Serum protein S100β in patients with malignant melanoma detected by an immunoluminometric assay

Journal of Cancer Research and Clinical Oncology

Volumn 126, Issue 2, 2000, Pages 107-110

  Wollina, Uwe ^a   Karte, Kerstin ^a   Hipler, Uta Christina ^a   Knöll, Brunhilde ^a   Kirsch, Karsten ^a   Herold, Claudia ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Malignant melanoma; S100 protein; Tumour markers

Indexed keywords

PROTEIN S 100; TUMOR MARKER; S100A1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; EARLY DIAGNOSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; BLOOD; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033621882     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050018     Document Type: Article

References (29)

1. Abraha HD, Fuller LC, Du Vivier AWP, Higgins EM, Sherwood RA (1997) Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 137:381-385
2. Banfalvi T, Bezzegh A, Edesne BM, Fejos Z, Liszkay G, Schumann B, Kremmer T, Otto S, Gilde K (1999) Determination of serum S-100 protein and 5-S-cysteinyl-DOPA levels in melanoma patients. Orv Hetil 140:599-602
3. Bonfrèr JMG, Korse CM, Nieweg OE, Rankin EM (1998) The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77:2210-2214
4. Buer J, Probst M, Franzke A, Duesing S, Haindl J, Volkenandt M, Wittke F, Hoffmann R, Ganser A (1997) Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 75:1373-1376
5. Cochran AJ, Lu HF, Li PX, Saxton R, Wen DR (1993) S-100 protein remains a practical marker for melanocytic lesions and other tumors. Melanoma Res 3:325-330
6. Couvrer T, Joos G, Geerts ML, Lambert J, Nayert J-M (1993) Neuron-specific enolase as serum marker in malignant melanoma. Lancet 342:1692-1695
7. Gaynor R, Irie R, Morton D, Herschman HR (1980) S100 protein is present in cultured human malignant melanomas. Nature 286:400-401
8. Guo H, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmüller D (1995) Clinical significance or serum S 100 in metastatic malignant melanoma. Eur J Cancer 31A:924-928
9. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E (1999a) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56:338-344
10. Hauschild A, Engel G, Brenner W, Gläser R, Monig H, Henze E, Christophers E (1999b) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140:1065-1071
11. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Gläser R, Henze E, Christophers E (1999c) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced melanoma patients. Melanoma Res 9:155-161
12. Henze G, Dummer R, Joller-Jemelka HI, Böni R, Burg G (1997) Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 194:208-212
13. Hirai S, Kageshita T, Kimura T, Tsujikasi M, Imai K, Wakamatsu K, Ito S, Ono T (1997) Serum levels of SCAM-1 and 5-cysteinyldopa as markers of melanoma progression. Melanoma Res 7:58-62
14. Jäckel A, Deichmann M, Waldmann V, Bock M, Näher H (1999) S-100beta-Protein im Serum als Tumormarker beim malignen Melanom. Aktueller Kenntnisstand und klinische Erfahrungen. Hautarzt 50:250-256
15. Kärnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B (1997) S100B protein, 5-5-cysteinyldopa and 6-hydroxy-5-metoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res 7:393-399
16. Klingman D, Hilt DC (1988) The S100 protein family. Trends Biochem Sci 13:437-443
17. Krähn G, Kaskel P, Rust A, Peter RU (1998) Serum-8100 bei metastasierendem Melanom. Münch Med Wochenschr 140:326-327
18. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini PA, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C, Van Voorhis N, Reintgen D (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3:558-563
19. Moore BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19:739-744
20. Mruck S, Baum RP, Rinne D, Hor G (1999) Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics. Anticancer Res 19:2685-2690
21. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K (1982) An immunoperoxidase study of S100 protein distribution in normal and neoplastic tissue. Am J Surg Pathol 7:715-727
22. Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbec (1994) Stellungnahme und Empfehlungen der Kommission malignes Melanom der Deutschen Dermatologischen Geselischaft zur Diagnostik, Behandlung und Nachsorge des malignen Melanoms der Haut. Stand 1993/94. Hautarzt 45:285-291
23. Schaider H, Rech-Weichselbaum I, Richtig E, Seidl H, Soyer HP, Smolle J, Kerl H (1997) Circulating adhesion molecules as prognostic factors for cutaneous melanoma. J Am Acad Dermatol 36:209-213
24. Schultz ES, Diepgen TL, von den Driesch P (1998) Clinical and prognostic relevance of serum S-100beta protein in malignant melanoma. Br J Dermatol 138:426-430
25. Seregni E, Massaron S, Martinetti A, Illeni MT, Rovini D, Belli F, Agresti R, Greco M, Cascinelli N, Bombardieri E (1998) S100 protein serum levels in cutaneous malignant melanoma. Oncol Rep 5:601-604
26. Von Schoultz E, Hansson LO, Djureen E, Hansson J, Karnell R, Nilsson B, Stigbrand T, Ringborg U (1996) Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res 6:133-137
27. Wollina U, Kilian U, Henkel U, Scharrschmidt H, Knopf B (1991) The initial steps of tumor progression in the melanocytic lineage - a histochemical approach. Anticancer Res 11:1405-1414
28. Wollina U, Karte K, Olbertz K, Hipler U-C (1998) Simultaneous measurement of circulating interellular adhesion molecule-1 and serum copper zinc dismutase activity in patients with malignant melanoma. Oncol Rep 5:473-476
29. Yang Q, O'Hanlon D, Heizmann CW, Marks A (1999) Demonstration of heterodimer formation between S100B and S100A6 in the yeast two-hybrid system and human melanoma. Exp Cell Res 246:501-509